199 related articles for article (PubMed ID: 22495388)
1. The role of antigen cross-presentation from leukemia blasts on immunity to the leukemia-associated antigen PR1.
Alatrash G; Ono Y; Sergeeva A; Sukhumalchandra P; Zhang M; St John LS; Yang TH; Ruisaard K; Armistead PM; Mittendorf EA; He H; Qiao N; Rodriguez-Cruz T; Liang S; Clise-Dwyer K; Wieder ED; Lizee G; Lu S; Molldrem JJ
J Immunother; 2012 May; 35(4):309-20. PubMed ID: 22495388
[TBL] [Abstract][Full Text] [Related]
2. Broad cross-presentation of the hematopoietically derived PR1 antigen on solid tumors leads to susceptibility to PR1-targeted immunotherapy.
Alatrash G; Mittendorf EA; Sergeeva A; Sukhumalchandra P; Qiao N; Zhang M; St John LS; Ruisaard K; Haugen CE; Al-Atrache Z; Jakher H; Philips AV; Ding X; Chen JQ; Wu Y; Patenia RS; Bernatchez C; Vence LM; Radvanyi LG; Hwu P; Clise-Dwyer K; Ma Q; Lu S; Molldrem JJ
J Immunol; 2012 Dec; 189(11):5476-84. PubMed ID: 23105141
[TBL] [Abstract][Full Text] [Related]
3. Targeting the Leukemia Antigen PR1 with Immunotherapy for the Treatment of Multiple Myeloma.
Alatrash G; Perakis AA; Kerros C; Peters HL; Sukhumalchandra P; Zhang M; Jakher H; Zope M; Patenia R; Sergeeva A; Yi S; Young KH; Philips AV; Cernosek AM; Garber HR; Qiao N; Weng J; St John LS; Lu S; Clise-Dwyer K; Mittendorf EA; Ma Q; Molldrem JJ
Clin Cancer Res; 2018 Jul; 24(14):3386-3396. PubMed ID: 29661776
[No Abstract] [Full Text] [Related]
4. Adoptive transfer of PR1 cytotoxic T lymphocytes associated with reduced leukemia burden in a mouse acute myeloid leukemia xenograft model.
Ma Q; Wang C; Jones D; Quintanilla KE; Li D; Wang Y; Wieder ED; Clise-Dwyer K; Alatrash G; Mj Y; Munsell MF; Lu S; Qazilbash MH; Molldrem JJ
Cytotherapy; 2010 Dec; 12(8):1056-62. PubMed ID: 20735170
[TBL] [Abstract][Full Text] [Related]
5. Processing and cross-presentation of individual HLA-A, -B, or -C epitopes from NY-ESO-1 or an HLA-A epitope for Melan-A differ according to the mode of antigen delivery.
Robson NC; McAlpine T; Knights AJ; Schnurr M; Shin A; Chen W; Maraskovsky E; Cebon J
Blood; 2010 Jul; 116(2):218-25. PubMed ID: 20430956
[TBL] [Abstract][Full Text] [Related]
6. ISCOMATRIX adjuvant induces efficient cross-presentation of tumor antigen by dendritic cells via rapid cytosolic antigen delivery and processing via tripeptidyl peptidase II.
Schnurr M; Orban M; Robson NC; Shin A; Braley H; Airey D; Cebon J; Maraskovsky E; Endres S
J Immunol; 2009 Feb; 182(3):1253-9. PubMed ID: 19155470
[TBL] [Abstract][Full Text] [Related]
7. Neuropilin-1 mediates neutrophil elastase uptake and cross-presentation in breast cancer cells.
Kerros C; Tripathi SC; Zha D; Mehrens JM; Sergeeva A; Philips AV; Qiao N; Peters HL; Katayama H; Sukhumalchandra P; Ruisaard KE; Perakis AA; St John LS; Lu S; Mittendorf EA; Clise-Dwyer K; Herrmann AC; Alatrash G; Toniatti C; Hanash SM; Ma Q; Molldrem JJ
J Biol Chem; 2017 Jun; 292(24):10295-10305. PubMed ID: 28468826
[TBL] [Abstract][Full Text] [Related]
8. Cross-presentation of synthetic long peptides by human dendritic cells: a process dependent on ERAD component p97/VCP but Not sec61 and/or Derlin-1.
Ménager J; Ebstein F; Oger R; Hulin P; Nedellec S; Duverger E; Lehmann A; Kloetzel PM; Jotereau F; Guilloux Y
PLoS One; 2014; 9(2):e89897. PubMed ID: 24587108
[TBL] [Abstract][Full Text] [Related]
9. Serine Proteases Enhance Immunogenic Antigen Presentation on Lung Cancer Cells.
Peters HL; Tripathi SC; Kerros C; Katayama H; Garber HR; St John LS; Federico L; Meraz IM; Roth JA; Sepesi B; Majidi M; Ruisaard K; Clise-Dwyer K; Roszik J; Gibbons DL; Heymach JV; Swisher SG; Bernatchez C; Alatrash G; Hanash S; Molldrem JJ
Cancer Immunol Res; 2017 Apr; 5(4):319-329. PubMed ID: 28254787
[TBL] [Abstract][Full Text] [Related]
10. Neutrophil elastase enhances antigen presentation by upregulating human leukocyte antigen class I expression on tumor cells.
Chawla A; Alatrash G; Philips AV; Qiao N; Sukhumalchandra P; Kerros C; Diaconu I; Gall V; Neal S; Peters HL; Clise-Dwyer K; Molldrem JJ; Mittendorf EA
Cancer Immunol Immunother; 2016 Jun; 65(6):741-51. PubMed ID: 27129972
[TBL] [Abstract][Full Text] [Related]
11. Tumor antigen processing and presentation depend critically on dendritic cell type and the mode of antigen delivery.
Schnurr M; Chen Q; Shin A; Chen W; Toy T; Jenderek C; Green S; Miloradovic L; Drane D; Davis ID; Villadangos J; Shortman K; Maraskovsky E; Cebon J
Blood; 2005 Mar; 105(6):2465-72. PubMed ID: 15546948
[TBL] [Abstract][Full Text] [Related]
12. The delivery of an antigen from the endocytic compartment into the cytosol for cross-presentation is restricted to early immature dendritic cells.
Hotta C; Fujimaki H; Yoshinari M; Nakazawa M; Minami M
Immunology; 2006 Jan; 117(1):97-107. PubMed ID: 16423045
[TBL] [Abstract][Full Text] [Related]
13.
Del Balzo D; Capmany A; Cebrian I; Damiani MT
Front Immunol; 2021; 12():662096. PubMed ID: 33936099
[TBL] [Abstract][Full Text] [Related]
14. Long-lasting cross-presentation of tumor antigen in human DC.
Faure F; Mantegazza A; Sadaka C; Sedlik C; Jotereau F; Amigorena S
Eur J Immunol; 2009 Feb; 39(2):380-90. PubMed ID: 19130478
[TBL] [Abstract][Full Text] [Related]
15. Prolonged antigen survival and cytosolic export in cross-presenting human gammadelta T cells.
Meuter S; Eberl M; Moser B
Proc Natl Acad Sci U S A; 2010 May; 107(19):8730-5. PubMed ID: 20413723
[TBL] [Abstract][Full Text] [Related]
16. Cross-presentation: underlying mechanisms and role in immune surveillance.
Rock KL; Shen L
Immunol Rev; 2005 Oct; 207():166-83. PubMed ID: 16181335
[TBL] [Abstract][Full Text] [Related]
17. Efficient cross-priming of tumor antigen-specific T cells by dendritic cells sensitized with diverse anti-MICA opsonized tumor cells.
Groh V; Li YQ; Cioca D; Hunder NN; Wang W; Riddell SR; Yee C; Spies T
Proc Natl Acad Sci U S A; 2005 May; 102(18):6461-6. PubMed ID: 15824323
[TBL] [Abstract][Full Text] [Related]
18. Control of dendritic cell cross-presentation by the major histocompatibility complex class I cytoplasmic domain.
Lizée G; Basha G; Tiong J; Julien JP; Tian M; Biron KE; Jefferies WA
Nat Immunol; 2003 Nov; 4(11):1065-73. PubMed ID: 14566337
[TBL] [Abstract][Full Text] [Related]
19. Thymoproteasome-Expressing Mesenchymal Stromal Cells Confer Protective Anti-Tumor Immunity
Bikorimana JP; El-Hachem N; El-Kadiry AE; Abusarah J; Salame N; Shammaa R; Rafei M
Front Immunol; 2020; 11():596303. PubMed ID: 33542714
[TBL] [Abstract][Full Text] [Related]
20. A proteasome-dependent, TAP-independent pathway for cross-presentation of phagocytosed antigen.
Merzougui N; Kratzer R; Saveanu L; van Endert P
EMBO Rep; 2011 Dec; 12(12):1257-64. PubMed ID: 22037009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
